Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients

Victoria G Hall^{1

2}, Benjamin W Teh^{1

2}

Affiliations

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

Editorial

Victoria G Hall et al. Transpl Infect Dis. 2023 Feb.

. 2023 Feb;25(1):e14005.

doi: 10.1111/tid.14005. Epub 2023 Jan 14.

Victoria G Hall^{1

2}, Benjamin W Teh^{1

2}

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

No abstract available

Keywords: COVID-19; antiviral; monoclonal antibody; stem cell transplant; treatment; vaccination.

References

1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436.
1. Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885-2894.
1. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193.
1. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586-2588.
1. Ra'ed Jabr AK, Anderson AD, Garcia LC, et al. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Transpl Infect Dis. 2023;25(1):e14006.